Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment
By Ben Glickman
Ligand Pharmaceuticals said its treatment for molluscum, a viral skin infection, had received approval from U.S. regulators.
The company said Friday that the U.S. Food and Drug Administration had approved Zelsuvmi, a topical prescription medication, to treat moluscum in adults and children one year old or older.
Ligand expects the treatment to be available in the U.S. in the second half of 2024.
The company said the FDA had approved Zelsuvmi as the first novel drug to treat mollescum infections.
Molluscum is a contagious skin infection which can cause lesions. It primarily affects children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 05, 2024 17:25 ET (22:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom